Billionaire Jeffrey Talpins Just Fled From These 5 Healthcare Stocks

2. BioNTech SE (NASDAQ:BNTX)

Former Value of Element Capital Management‘s 13F Position: $40.1 million

Number of Hedge Fund Shareholders: 29

Element Capital was also loading up on another major player in the vaccine space during Q4, BioNTech SE (NASDAQ:BNTX), which has a strong vaccine collaboration in place with Pfizer Inc. (NYSE:PFE), which had ranked as Element Capital’s top stock pick at the end of last year. The fund unloaded nearly its entire Pfizer stake during Q1, and did sell off its entire BNTX position during the quarter as it looks to target other investment areas.

BioNTech SE (NASDAQ:BNTX) has been the beneficiary of the some of the same positive news as Moderna, with the U.S government recently ordering another 105 million doses of the company’s Comirnaty vaccine, with an option to purchase a further 195 million doses. Pfizer estimated the companies’ co-developed vaccine would generate $32 billion in sales this year.

BioNTech SE (NASDAQ:BNTX) also has a booster candidate that’s currently in phase 2/3 testing which has shown strong efficacy against several omicron variants, including the most dominant strains. A resurgence of Covid would certainly be a short-term boon for the company, which pulled in $22 billion in revenue last year, a figure that analysts predict will crash to just $3.1 billion by 2026.